AbbVie Writes Off $3.5B on Cerevel Drug After Phase 2 Failures

AbbVie has announced a significant financial write-off of $3.5 billion related to a drug developed by Cerevel Therapeutics, following the drug's failure in Phase 2 clinical trials. This decision underscores the challenges and risks associated with drug development, particularly in the later stages of clinical testing. The write-off reflects the company's reassessment of the drug's potential in light of the trial outcomes, marking a pivotal moment in AbbVie's investment and development strategy.